Use of levodopa decarbozylase inhibitor

No definition available.

Endpoint definition

↥

FinnGen phenotype data

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC N04BA02

Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Extra metadata

First used in FinnGen datafreeze DF2

↥

List of similar endpoints to Use of levodopa decarbozylase inhibitor based on the number of shared cases.

Broader endpoints:

None

Narrower endpoints:

None

↥

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

↥

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarbozylase inhibitor
GWS hits:

↥

before Use of levodopa decarbozylase inhibitor
after Use of levodopa decarbozylase inhibitor

Loading survival analyses plot

Loading survival analyses table

↥